weight loss glp 1 GLP-1 drugs leave users low on key nutrients, study finds Comparing Ozempic, Wegovy and Other
Description
Tuttle, K
Gallwitz, Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes, Diabetes Metab
doi: 10.3810/pgm.2011.09.2479
This dynamic has played out with semaglutide already, where compounded semaglutide remains popular despite approved versions being available
doi: 10.2337/db22-719-P
Patients with T2DM are also at an increased risk of myocardial infarction, stroke, and other major adverse cardiac events (MACE) [11]
